
Barbara Ruozi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3545132/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	PLA/PLGA nanoparticles for sustained release of docetaxel. International Journal of Pharmaceutics, 2006, 325, 172-179.	5.2	383
2	Targeting the central nervous system: In vivo experiments with peptide-derivatized nanoparticles loaded with Loperamide and Rhodamine-123. Journal of Controlled Release, 2007, 122, 1-9.	9.9	217
3	Polymeric nanoparticles for the drug delivery to the central nervous system. Expert Opinion on Drug Delivery, 2008, 5, 155-174.	5.0	189
4	AFM, ESEM, TEM, and CLSM in liposomal characterization: a comparative study. International Journal of Nanomedicine, 2011, 6, 557.	6.7	150
5	Nanoparticle transport across the blood brain barrier. Tissue Barriers, 2016, 4, e1153568.	3.2	121
6	Potential Use of Polymeric Nanoparticles for Drug Delivery Across the Blood-Brain Barrier. Current Medicinal Chemistry, 2013, 20, 2212-2225.	2.4	113
7	Atomic force microscopy and photon correlation spectroscopy: Two techniques for rapid characterization of liposomes. European Journal of Pharmaceutical Sciences, 2005, 25, 81-89.	4.0	112
8	Sialic acid and glycopeptides conjugated PLGA nanoparticles for central nervous system targeting: In vivo pharmacological evidence and biodistribution. Journal of Controlled Release, 2010, 145, 49-57.	9.9	110
9	Protein corona and nanoparticles: how can we investigate on?. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2017, 9, e1467.	6.1	93
10	Cholesterolâ€loaded nanoparticles ameliorate synaptic and cognitive function in <scp>H</scp> untington's disease mice. EMBO Molecular Medicine, 2015, 7, 1547-1564.	6.9	84
11	Nanosystems based on siRNA silencing HuR expression counteract diabetic retinopathy in rat. Pharmacological Research, 2016, 111, 713-720.	7.1	84
12	Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood–brain barrier. Nanomedicine, 2011, 6, 423-436.	3.3	80
13	Application of atomic force microscopy to characterize liposomes as drug and gene carriers. Talanta, 2007, 73, 12-22.	5.5	78
14	Preparation and optimization of PIT solid lipid nanoparticles via statistical factorial design. European Journal of Medicinal Chemistry, 2012, 49, 110-117.	5.5	75
15	Targeted Polymeric Nanoparticles for Brain Delivery of High Molecular Weight Molecules in Lysosomal Storage Disorders. PLoS ONE, 2016, 11, e0156452.	2.5	72
16	Reduced plaque size and inflammation in the APP23 mouse model for Alzheimer's disease after chronic application of polymeric nanoparticles for CNS targeted zinc delivery. Journal of Trace Elements in Medicine and Biology, 2018, 49, 210-221.	3.0	64
17	Insight on the fate of CNS-targeted nanoparticles. Part I: Rab5-dependent cell-specific uptake and distribution. Journal of Controlled Release, 2014, 174, 195-201.	9.9	63
18	Re-dispersible cationic solid lipid nanoparticles (SLNs) freeze-dried without cryoprotectors: Characterization and ability to bind the pEGFP-plasmid. European Journal of Pharmaceutics and Biopharmaceutics, 2007, 67, 320-328.	4.3	61

#	Article	IF	CITATIONS
19	PEG-g-chitosan nanoparticles functionalized with the monoclonal antibody OX26 for brain drug targeting. Nanomedicine, 2015, 10, 1735-1750.	3.3	60
20	The "fate―of polymeric and lipid nanoparticles for brain delivery and targeting: Strategies and mechanism of blood–brain barrier crossing and trafficking into the central nervous system. Journal of Drug Delivery Science and Technology, 2016, 32, 66-76.	3.0	58
21	pDNA condensation capacity and in vitro gene delivery properties of cationic solid lipid nanoparticles. International Journal of Pharmaceutics, 2010, 389, 254-261.	5.2	57
22	PLGA Nanoparticles Loaded Cerebrolysin: Studies on Their Preparation and Investigation of the Effect of Storage and Serum Stability with Reference to Traumatic Brain Injury. Molecular Neurobiology, 2015, 52, 899-912.	4.0	57
23	Sustained Zeroâ€Order Release of Intact Ultraâ€Stable Drug‣oaded Liposomes from an Implantable Nanochannel Delivery System. Advanced Healthcare Materials, 2014, 3, 230-238.	7.6	48
24	Insight on the fate of CNS-targeted nanoparticles. Part II: Intercellular neuronal cell-to-cell transport. Journal of Controlled Release, 2014, 177, 96-107.	9.9	48
25	Protein cage nanostructure as drug delivery system: magnifying glass on apoferritin. Expert Opinion on Drug Delivery, 2017, 14, 825-840.	5.0	47
26	Targeting Brain Disease in MPSII: Preclinical Evaluation of IDS-Loaded PLGA Nanoparticles. International Journal of Molecular Sciences, 2019, 20, 2014.	4.1	47
27	Development of Novel Zn2+ Loaded Nanoparticles Designed for Cell-Type Targeted Drug Release in CNS Neurons: In Vitro Evidences. PLoS ONE, 2011, 6, e17851.	2.5	46
28	Endocytosis of Nanomedicines: The Case of Glycopeptide Engineered PLGA Nanoparticles. Pharmaceutics, 2015, 7, 74-89.	4.5	46
29	PLGA-PEG-ANG-2 Nanoparticles for Blood–Brain Barrier Crossing: Proof-of-Concept Study. Pharmaceutics, 2020, 12, 72.	4.5	46
30	NIR-labeled nanoparticles engineered for brain targeting: in vivo optical imaging application and fluorescent microscopy evidences. Journal of Neural Transmission, 2011, 118, 145-153.	2.8	45
31	Can leptin-derived sequence-modified nanoparticles be suitable tools for brain delivery?. Nanomedicine, 2012, 7, 365-382.	3.3	44
32	Nanomedicine in Alzheimer's disease: Amyloid beta targeting strategy. Progress in Brain Research, 2019, 245, 57-88.	1.4	39
33	Cationic Liposomes for Gene Transfection. Journal of Drug Targeting, 2003, 11, 407-414.	4.4	36
34	Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): <i>In Vivo</i> Experiments. Molecular Pharmaceutics, 2015, 12, 3672-3684.	4.6	36
35	Insights into kinetics, release, and behavioral effects of brain-targeted hybrid nanoparticles for cholesterol delivery in Huntington's disease. Journal of Controlled Release, 2021, 330, 587-598.	9.9	33
36	Applications of the ROS-Responsive Thioketal Linker for the Production of Smart Nanomedicines. Polymers, 2022, 14, 687.	4.5	33

#	Article	IF	CITATIONS
37	Colloidal systems for CNS drug delivery. Progress in Brain Research, 2009, 180, 35-69.	1.4	32
38	Sialic acid as a potential approach for the protection and targeting of nanocarriers. Expert Opinion on Drug Delivery, 2011, 8, 921-937.	5.0	31
39	ROS-responsive "smart―polymeric conjugate: Synthesis, characterization and proof-of-concept study. International Journal of Pharmaceutics, 2019, 570, 118655.	5.2	31
40	PLA-microparticles formulated by means a thermoreversible gel able to modify protein encapsulation and release without being co-encapsulated. International Journal of Pharmaceutics, 2006, 323, 131-138.	5.2	30
41	Nanoparticles Engineered with Rituximab and Loaded with Nutlin-3 Show Promising Therapeutic Activity in B-Leukemic Xenografts. Clinical Cancer Research, 2013, 19, 3871-3880.	7.0	30
42	Doxorubicin Hydrochloride-Loaded Nonionic Surfactant Vesicles to Treat Metastatic and Non-Metastatic Breast Cancer. ACS Omega, 2021, 6, 2973-2989.	3.5	30
43	Current Strategies for the Delivery of Therapeutic Proteins and Enzymes to Treat Brain Disorders. International Review of Neurobiology, 2017, 137, 1-28.	2.0	27
44	Neurotrophic Factors and Neurodegenerative Diseases. International Review of Neurobiology, 2012, 102, 207-247.	2.0	26
45	Brain-targeted polymeric nanoparticles: <i>in vivo</i> evidence of different routes of administration in rodents. Nanomedicine, 2013, 8, 1373-1383.	3.3	26
46	Hybrid nanoparticles as a new technological approach to enhance the delivery of cholesterol into the brain. International Journal of Pharmaceutics, 2018, 543, 300-310.	5.2	26
47	Collagen-based modified membranes for tissue engineering: Influence of type and molecular weight of GAGs on cell proliferation. International Journal of Pharmaceutics, 2009, 378, 108-115.	5.2	25
48	AFM phase imaging of soft-hydrated samples: A versatile tool to complete the chemical-physical study of liposomes. Journal of Liposome Research, 2009, 19, 59-67.	3.3	25
49	Chemico-physical investigation of tenofovir loaded polymeric nanoparticles. International Journal of Pharmaceutics, 2012, 436, 753-763.	5.2	25
50	Nuclear localization of cationic solid lipid nanoparticles containing Protamine as transfection promoter. European Journal of Pharmaceutics and Biopharmaceutics, 2010, 76, 384-393.	4.3	23
51	Anticancer drug-loaded quantum dots engineered polymeric nanoparticles: Diagnosis/therapy combined approach. European Journal of Pharmaceutical Sciences, 2017, 107, 230-239.	4.0	23
52	Nanoparticles as Blood–Brain Barrier Permeable CNS Targeted Drug Delivery Systems. Topics in Medicinal Chemistry, 2013, , 71-89.	0.8	22
53	Preparation, characterization and photostability assessment of curcumin microencapsulated within methacrylic copolymers. Journal of Drug Delivery Science and Technology, 2016, 33, 88-97.	3.0	22
54	Nanomedicine: the future for advancing medicine and neuroscience. Nanomedicine, 2012, 7, 1113-1116.	3.3	21

Barbara Ruozi

#	Article	IF	CITATIONS
55	Synthesis, Characterization, and In Vitro Studies of an Reactive Oxygen Species (ROS)-Responsive Methoxy Polyethylene Glycol-Thioketal-Melphalan Prodrug for Glioblastoma Treatment. Frontiers in Pharmacology, 2020, 11, 574.	3.5	21
56	Poly (D,L-Lactide-co-Glycolide) Nanoparticles Loaded with Cerebrolysin Display Neuroprotective Activity in a Rat Model of Concussive Head Injury. CNS and Neurological Disorders - Drug Targets, 2014, 13, 1475-1482.	1.4	21
57	Novel peptide-conjugated nanomedicines for brain targeting: In vivo evidence. Nanomedicine: Nanotechnology, Biology, and Medicine, 2020, 28, 102226.	3.3	20
58	Nanotechnology and Alzheimer's Disease: What has been Done and What to Do'. Current Medicinal Chemistry, 2014, 21, 4169-4185.	2.4	20
59	Ketorolac Tromethamine Liposomes: Encapsulation and Release Studies. Journal of Liposome Research, 2005, 15, 175-185.	3.3	18
60	Detection of PLGA-based nanoparticles at a single-cell level by synchrotron radiation FTIR spectromicroscopy and correlation with X-ray fluorescence microscopy. International Journal of Nanomedicine, 2014, 9, 2791.	6.7	18
61	EXPLOITING THE VERSATILITY OF CHOLESTEROL IN NANOPARTICLES FORMULATION. International Journal of Pharmaceutics, 2016, 511, 331-340.	5.2	18
62	Nanomedicine Against Aβ Aggregation by β–Sheet Breaker Peptide Delivery: In Vitro Evidence. Pharmaceutics, 2019, 11, 572.	4.5	18
63	Amphiphilic ion pairs of tobramycin with lipoamino acids. European Journal of Medicinal Chemistry, 2011, 46, 1665-1671.	5.5	17
64	Characterization of lysosome-destabilizing DOPE/PLGA nanoparticles designed for cytoplasmic drug release. International Journal of Pharmaceutics, 2014, 471, 349-357.	5.2	17
65	PEGylated siRNA lipoplexes for silencing of BLIMP-1 in Primary Effusion Lymphoma: In vitro evidences of antitumoral activity. European Journal of Pharmaceutics and Biopharmaceutics, 2016, 99, 7-17.	4.3	17
66	Curcumin Loaded Polymeric vs. Lipid Nanoparticles: Antioxidant Effect on Normal and Hypoxic Olfactory Ensheathing Cells. Nanomaterials, 2021, 11, 159.	4.1	17
67	Title is missing!. Journal of Inclusion Phenomena and Macrocyclic Chemistry, 2000, 37, 237-251.	1.6	16
68	Cidofovir-loaded liposomes: an intro-study using BCBL-1 cell line as a model for primary effusion lymphoma. European Journal of Pharmaceutical Sciences, 2010, 41, 254-264.	4.0	16
69	Amphiphilic Erythromycin-Lipoamino Acid Ion Pairs: Characterization and In Vitro Microbiological Evaluation. AAPS PharmSciTech, 2011, 12, 468-475.	3.3	16
70	The role of protamine amount in the transfection performance of cationic SLN designed as a gene nanocarrier. Drug Delivery, 2012, 19, 1-10.	5.7	16
71	Brain targeting with polymeric nanoparticles: which administration route should we take?. Nanomedicine, 2013, 8, 1361-1363.	3.3	16
72	Apoferritin nanocage as drug reservoir: is it a reliable drug delivery system?. Expert Opinion on Drug Delivery, 2016, 13, 1341-1343.	5.0	16

#	Article	IF	CITATIONS
73	Investigating Novel Syntheses of a Series of Unique Hybrid PLGA-Chitosan Polymers for Potential Therapeutic Delivery Applications. Polymers, 2020, 12, 823.	4.5	16
74	Nanomedicine and neurodegenerative disorders: so close yet so far. Expert Opinion on Drug Delivery, 2015, 12, 1041-1044.	5.0	15
75	Apoferritin nanocage as streptomycin drug reservoir: Technological optimization of a new drug delivery system. International Journal of Pharmaceutics, 2017, 518, 281-288.	5.2	14
76	Enzyme Stability in Nanoparticle Preparations Part 1: Bovine Serum Albumin Improves Enzyme Function. Molecules, 2020, 25, 4593.	3.8	14
77	Evidence of the Existence of 2:1 Guest–Host Complexes between Diclofenac and Cyclodextrins in D2O Solutions. A 1H and 13C NMR Study on Diclofenac/l²-Cyclodextrin and Diclofenac/2-Hydroxypropyl-l²-cyclodextrin Systems. Journal of Chemical Research Synopses, 1999, , 414-415.	0.3	13
78	Intact collagen and atelocollagen sponges: Characterization and ESEM observation. Materials Science and Engineering C, 2007, 27, 802-810.	7.3	13
79	Antioxidant activity and photostability assessment of trans-resveratrol acrylate microspheres. Pharmaceutical Development and Technology, 2019, 24, 222-234.	2.4	13
80	DOTAP/UDCA vesicles: novel approach in oligonucleotide delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2007, 3, 1-13.	3.3	12
81	Biodegradable device applied in flatfoot surgery: Comparative studies between clinical and technological aspects of removed screws. Materials Science and Engineering C, 2013, 33, 1773-1782.	7.3	12
82	Nanoparticles Loaded with Nutlin-3 Display Cytotoxicity Towards p53 ^{wildtype} JVM-2 But Not Towards p53 ^{mutated} BJAB Leukemic Cells. Current Medicinal Chemistry, 2013, 20, 2712-2722.	2.4	12
83	AFM and TEM characterization of siRNAs lipoplexes: A combinatory tools to predict the efficacy of complexation. Colloids and Surfaces A: Physicochemical and Engineering Aspects, 2013, 436, 459-466.	4.7	11
84	Qualitative and semiquantitative analysis of the protein coronas associated to different functionalized nanoparticles. Nanomedicine, 2018, 13, 407-422.	3.3	11
85	Lipid Nanoparticle Inclusion Prevents Capsaicin-Induced TRPV1 Defunctionalization. Pharmaceutics, 2020, 12, 339.	4.5	11
86	Tween® Preserves Enzyme Activity and Stability in PLGA Nanoparticles. Nanomaterials, 2021, 11, 2946.	4.1	11
87	Tunneling Nanotubes: A New Target for Nanomedicine?. International Journal of Molecular Sciences, 2022, 23, 2237.	4.1	11
88	Vegetable cells in Papanicolaou-stained cervical smears. Diagnostic Cytopathology, 2006, 34, 45-49.	1.0	10
89	Novel polymeric/lipidic hybrid systems (PLHs) for effective Cidofovir delivery: Preparation, characterization and comparative in vitro study with polymeric particles and liposomes. International Journal of Pharmaceutics, 2011, 413, 220-228.	5.2	10
90	Nutlin-3 loaded nanocarriers: Preparation, characterization and in vitro antineoplastic effect against primary effusion lymphoma. International Journal of Pharmaceutics, 2015, 490, 85-93.	5.2	10

Barbara Ruozi

#	Article	IF	CITATIONS
91	Liposome-oligonucleotides interaction for in vitro uptake by COS I and HaCaT cells. Journal of Drug Targeting, 2005, 13, 295-304.	4.4	9
92	Antineoplastic effects of liposomal short interfering RNA treatment targeting BLIMP1/PRDM1 in primary effusion lymphoma. Haematologica, 2015, 100, e467-e470.	3.5	9
93	Microfluidic Technology for the Production of Hybrid Nanomedicines. Pharmaceutics, 2021, 13, 1495.	4.5	9
94	Comparison between Roesy and ¹³ C NMR Complexation Shifts in Deriving the Geometry of Inclusion Compounds: A Study on the Interaction between Hyodeoxycholic Acid and 2-Hydroxypropyl-β-Cyclodextrin. Supramolecular Chemistry, 2001, 12, 427-433.	1.2	8
95	Immunoliposomal systems targeting primary effusion lymphoma: <i>in vitro</i> study. Nanomedicine, 2010, 5, 1051-1064.	3.3	8
96	Application of poly-L-lactide screws in flat foot surgery: histological and radiological aspects of bio-absorption of degradable devices. Histology and Histopathology, 2012, 27, 485-96.	0.7	8
97	Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain. CNS and Neurological Disorders - Drug Targets, 2016, 15, 1079-1091.	1.4	8
98	The loading of labelled antibody-engineered nanoparticles with Indinavir increases itsin vitroefficacy againstCryptosporidium parvum. Parasitology, 2011, 138, 1384-1391.	1.5	7
99	Development, Optimization and Characterization of Eudraguard®-Based Microparticles for Colon Delivery. Pharmaceuticals, 2020, 13, 131.	3.8	7
100	Glioblastoma Multiforme Selective Nanomedicines for Improved Anti-Cancer Treatments. Pharmaceutics, 2022, 14, 1450.	4.5	7
101	Flow cytometry and live confocal analysis for the evaluation of the uptake and intracellular distribution of FITC-ODN into HaCaT cells. Journal of Liposome Research, 2009, 19, 241-251.	3.3	6
102	Functionalization of liposomes: microscopical methods for preformulative screening. Journal of Liposome Research, 2015, 25, 150-156.	3.3	6
103	Synthesis, characterization and inÂvitro evaluation of amphiphilic ion pairs of erythromycin and kanamycin antibiotics with liposaccharides. European Journal of Medicinal Chemistry, 2016, 120, 329-337.	5.5	6
104	Preparation and Microbiological Evaluation of Amphiphilic Kanamycin-Lipoamino Acid Ion-Pairs. Antibiotics, 2014, 3, 216-232.	3.7	4
105	Nanoimaging: photophysical and pharmaceutical characterization of poly-lactide-co-glycolide nanoparticles engineered with quantum dots. Nanotechnology, 2016, 27, 015704.	2.6	4
106	In vitro treatment of congenital disorder of glycosylation type Ia using PLGA nanoparticles loaded with GDP‑Man. International Journal of Molecular Medicine, 2019, 44, 262-272.	4.0	4
107	Nanoparticles for Brain Delivery of Drugs: In <i>Vivo</i> Experiments and Mechanism of Blood-Brain Barrier Crossing. American Journal of Neuroprotection and Neuroregeneration, 2011, 3, 13-20.	0.1	2
108	The Bridge Between Nanotechnology and Neuroscience: Neuro-Nanomedicine. Journal of Nanoneuroscience, 2012, 2, 20-26.	0.5	2

#	Article	IF	CITATIONS
109	Development and Validation of a New Storage Procedure to Extend the In-Use Stability of Azacitidine in Pharmaceutical Formulations. Pharmaceuticals, 2021, 14, 943.	3.8	1
110	Nanomedicines for brain diseases: where we are and where we are going. Therapeutic Delivery, 2021, 12, 631-635.	2.2	1
111	I14â€Translational potential of cholesterol supplementation-based strategies for huntington's disease. , 2018, , .		1
112	Nanotechonology for Drug Targeting. Advances in Science and Technology, 0, , .	0.2	0
113	L16â€Identifying a therapeutic regimen for cholesterol delivery to huntington's disease brain. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, A95.2-A95.	1.9	0
114	Glycopeptide-Decorated Nanoparticles as Drug Carriers for CNS: Effects of Surface Coverage and Carbohydrate Type. Journal of Nanoneuroscience, 2009, 1, 152-157.	0.5	0
115	Immunonanosystems to CNS Pathologies. , 2012, , 107-168.		0